Previous 10 | Next 10 |
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
NESS ZIONA, Israel, Jan. 02, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) today announced the initiation of a Phase 1 proof of concept clinical study of SGT-210, its novel, topical, epidermal growth factor receptor inhibitor in patients with punctate palmoplantar kerat...
Shares of Sol-Gel Technologies (NASDAQ: SLGL) rose as much as 36.2% today after the company announced positive results for its acne treatment Twyneo in multiple phase 3 clinical trials. The drug candidate met all three primary endpoints at the 12-week mark across both studies, including the ...
Neovasc (NASDAQ: NVCN ) +121% files U.S. application for Reducer. More news on: Neovasc Inc., FuelCell Energy, Inc., Sol-Gel Technologies Ltd., Stocks on the move, Read more ...
Gainers: Savara (NASDAQ: SVRA ) +98% . More news on: Savara Inc., NIO Limited, Sol-Gel Technologies Ltd., Stocks on the move, Read more ...
Sol-Gel Technologies (NASDAQ: SLGL ) +160% on Twyneo successful in acne studies. More news on: Sol-Gel Technologies Ltd., Savara Inc., NIO Limited, Stocks on the move, Read more ...
Ultra-thinly traded micro cap Sol-Gel Technologies (NASDAQ: SLGL ) rockets 148% premarket, albeit on turnover of only 43K shares, in response to positive results from two Phase 3 clinical trials, SGT-65-04 and SGT-65-05 , evaluating topical cream Twyneo (microencapsulated tr...
All co-primary endpoints achieved in both Phase 3 clinical trials Twyneo was well-tolerated and the majority of local skin reactions, when reported, were mild and improved over time Additional data to be shared during the January 8 th investor conference call and webcast NESS...
Sol-Gel Technologies (NASDAQ: SLGL ): Q3 GAAP EPS of -$0.37 misses by $0.14 . More news on: Sol-Gel Technologies Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
Top-line generic product revenue of $4.7 million in the third quarter Results from TWIN Phase 3 trials in acne vulgaris remain on track for the fourth quarter of 2019 NESS ZIONA, Israel, Nov. 13, 2019 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage ...
News, Short Squeeze, Breakout and More Instantly...
Sol-Gel Technologies Ltd. Company Name:
SLGL Stock Symbol:
NASDAQ Market:
Sol-Gel Technologies Ltd. Website:
NESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved...
NESS ZIONA, Israel, May 28, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved ...